Depsides and depsidones
Medchemexpress LLC SOR-C13 | 1187852-48-7 | 99.1% | 1565.81 | 5 MG
SOR-C13 is a carboxy-terminal truncated peptide, functioning as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer. SOR-C13 demonstrates anticancer activity.
- Functions as a high-affinity TRPV6 antagonist
- Has an IC50 value of 14 nM against TRPV6
- Associated with anticancer activity
- Inhibits tumor growth in female NOD/SCID mice with SKOV-3 cells
Medchemexpress LLC Sodium benzoate | 532-32-1 | MFCD00012463 | 99.6% | 144.10 | C7H5NaO2 | 1mL
Sodium benzoate is an orally active pharmaceutical excipient such as an antibacterial agent preservative lubricant etc Pharmaceutical excipients or pharmaceutical auxiliaries refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations which can improve the stability solubility and processability of pharmaceutical preparations Pharmaceutical excipients also affect the absorption distribution metabolism and elimination (ADME) processes of co-administered drugs Sodium benzoate activates NF- B and induces Apoptosis Sodium benzoate induces immune suppression and produces reproductively toxic Sodium benzoate can be used for colon cancer and immune disease research[1][2][3][4][5]
Medchemexpress LLC SOR-C13 | 1187852-48-7 | 99.1% | 1565.81 | 10 MG
SOR-C13 is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It exhibits anticancer activity by targeting TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM
- Demonstrates anticancer activity
- Targets TRPV6, a non-voltage gated calcium channel
- Effectively inhibits tumor growth in relevant animal models
Medchemexpress LLC Sor-c13 TFA | 1187852-48-7 | 99.3% | 1565.81 | 25 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide. It functions as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA exhibits anticancer activity.
- High-affinity TRPV6 antagonist with an IC50 value of 14 nM.
- Associated with malignancy and poor prognosis in breast cancer.
- Exhibits anticancer activity.
- For research use only.
- Not for sale to patients.
Medchemexpress LLC Sor-C13 Tfa | 99.3% | 1565.81 (free acid) | 10 MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. It has shown anticancer activity and targets TRPV6, a non-voltage gated calcium channel associated with malignancy and poor prognosis in breast cancer.
- High-affinity TRPV6 antagonist
- Exhibits anticancer activity
- Targets non-voltage gated calcium channel TRPV6
- Potentially useful in breast cancer research